Brain-activated therapy

for stroke recovery.

Non-invasive therapy for motor function
rehabilitation with IpsiHandTM

IpsiHandâ„¢ is an FDA-cleared non-invasive device for rehabilitation of upper extremity motor function after stroke.

What is IpsiHand?

The IpsiHand is the first FDA-cleared device leveraging brain-computer interface (BCI) technology to assist chronic stroke patients in rehabilitation.

The device utilizes the uninjured, or ipsilateral, side of the brain to improve arm and hand function.

Therapeutic device with

long-lasting results.

IpsiHand results are durable and retained. Six months after using IpsiHand, improvements in upper extremity function remained consistent.

This sets IpsiHand apart from other rehabilitation technologies, which typically show no carryover in function.

+10.2 AMAT

On the AMAT
(Arm Motor Ability Test).

Are your patients the right fit?

Many stroke recovery patients have the cognitive capabilities needed to make progress, but just don’t feel like their brain and body are connecting. IpsiHand is a great fit for motivated patients ready to take ownership in their recovery journey.

Here are three criteria to determine if a patient might be a good fit:

ï„‘

01

They are struggling with a plateau in their recovery.

ï„‘

02

They are ready to make advancements in regaining use of their upper extremity.

ï„‘

03

They are looking to enhance their current therapy program.

Why IpsiHand?

Scientifically-backed and Clinically-tested

Unlike other BCI-based technologies, IpsiHand is a non-surgical, non-invasive
technology that is recognized by CMS with a HCPCS code. It leverages contralesional-controlled BCI-therapy to effectively enable recovery for chronic hemiparesis.

The EEG headset pulls cortical signals from hand regions in the primary cortex of the ipsilateral cerebral hemisphere, sending them to the computer processor to make the handpiece move in real time. With regular use following exercise prompts on their tablet, IpsiHand users show the presence of biomarkers in the brain that demonstrates motor remodeling.

Convenience and Ease of Access

Often, the intensity required for motor improvement isn’t achieved in outpatient therapy alone. That’s why IpsiHand is designed for independent use by patients at home. By improving patient access to home therapy, IpsiHand users can log more therapeutic program hours without direct supervision of an occupational or physical therapist.

By using the IpsiHand, patients can have improved access, reduced impacts from the social determinants of health, and avoid transportation-related restrictions. Ultimately, this therapy option can increase the potential for significant cost savings compared to other therapeutic neuro-technologies.

Prescribing IpsiHand: The Process

Identifying Ideal Candidates

Patients are indicated to use IpsiHand if they are chronic stroke patients (≥ six months post-stroke), age 18 or older, and undergoing rehabilitation to facilitate muscle re-education and maintaining or increasing range of motion in the upper extremity.

Prescribing IpsiHand

Standard prescription and insurance forms are available in our clinical resource center for your convenience. These include all necessary and supplemental information for prescribing IpsiHand System to your patients.

What’s Next?

Upon receipt of a valid prescription and insurance approval for coverage, the Neurolutions clinical staff works with the patient to schedule an EEG Signal Test and evaluate the patient’s motor intent signals. This crucial step ensures the patient is a suitable candidate for the IpsiHand.

Clinically-Backed Claims

FDA

IpsiHand is FDA Cleared
– via De Novo …read more

RX

Nemo enim ipsam voluptatem quia voluptas sit asperna.

CLSA

Nemo enim ipsam voluptatem quia voluptas sit asperna.

NIH

IpsiHand is FDA Cleared
– via De Novo …read more

First clinical

trial complete. Published on Cover of Stroke.

Target Replacement

Nemo enim ipsam voluptatem quia voluptas sit asperna.